AUR-103

News alerts, weekly reports and conference planners

Company:

Dr. Reddy’s

Drug class:

CD47 antagonist

‹

›

8ms

A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)

P1/2, N=18, Recruiting, Aurigene Discovery Technologies Limited

8 months ago

New P1/2 trial

Herceptin (trastuzumab) • capecitabine • oxaliplatin • AUR-103

almost3years

PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES (EHA 2023)

Subsequent to determining the OBD of single agent AUR103, combination studies with azacitidine and/or azacitidine/Venetoclax and/or ADCC competent antibodies will be studied in relevant tumor types. AUR103 is a novel First in Class small molecule inhibitor of CD47. The First in Human trial (AUR103-101; BHARAT) is currently enrolling. The preliminary safety in the first two cohorts appears commensurate with "lack of haemolysis" in non-clinical models.

almost 3 years ago

Clinical • P1 data • Metastases

CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)

Venclexta (venetoclax) • azacitidine • AUR-103